Magnolini Raphael, Kossinna Kuvinda, Bjasch Daniel, Kruijver Muriel, Bruggmann Philip, Senn Oliver
Arud Centre for Addiction Medicine, Zurich, Switzerland.
Institute of Primary Care, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Swiss Med Wkly. 2025 Feb 6;155:4225. doi: 10.57187/s.4225.
The non-medical use of anabolic androgenic steroids for the improvement of aesthetic and sports performance purposes has become a global substance use disorder, particularly among men in recreational sports. Health outcomes among people who are using anabolic androgenic steroids may be detrimental, yet healthcare services for these users are scarce. Therefore, the aim of this project was to conduct a quality assurance study to evaluate the feasibility of providing current best clinical practice for anabolic androgenic steroids users based on the published literature within a primary care practice in Zurich (Switzerland).
A primary healthcare practice for current or past anabolic androgenic steroids use was established at the Arud Centre for Addiction Medicine in Zurich providing specialised medical care for this population. The reporting and methodology to evaluate feasibility of this quality assurance study follow a checklist for pilot studies. The primary feasibility outcomes for this study were satisfaction with the services received (customer satisfaction score), as well as loyalty towards the services (net promoter score). These customer metrics have been used successfully in the medical field to measure patient experiences, as well as infer future word-of-mouth advertisement (i.e. return and refer). Furthermore, the objective was to describe patient characteristics and substance use behaviours in a Swiss context. Patients could access these services in Zurich from 1 June 2023 onwards. The recruitment strategy was word-of-mouth advertising among anabolic androgenic steroids users and paper advertisement (i.e. flyers) about the healthcare service. Eligibility criteria were based on legal restrictions regarding doping laws and professional ethical principles of medicine. In an initial visit at the practice, a focused patient history was assessed, and patients received a physical, psychometric, instrumental as well as laboratory examination. Datasets are summarised using descriptive statistics.
Overall, 34 eligible patients were seen over the period from June until December 2023. Excellent results regarding loyalty towards the service (net promoter score: 100; integer) as well as patient satisfaction with the received services (customer satisfaction score: 100%) were achieved. Patients were commonly young professional males (mean: 38.5 years, standard deviation: 8 years), with educational level beyond compulsory schooling. The main motivation for using anabolic androgenic steroids was aesthetic purposes. Acquisition of these substances occurred mostly through non-medical sources. Patterns of anabolic androgenic steroids use were complex with extensive polypharmacy and concomitant illicit substance use. Most patients suffered from side effects with multiple physical as well as mental health complications. Many abnormal findings were found regarding the physical as well as laboratory and instrumental examination, although mostly mild and transient, some possibly severe regarding health outcomes.
With this first quality assurance study, we demonstrate that integration of current best clinical practice for anabolic androgenic steroids users in recreational sports appears to be feasible with high acceptance in a Swiss primary care practice. Furthermore, those patients may engage in high-risk behaviours and a high prevalence of comorbid medical conditions was demonstrated. Anabolic androgenic steroids users likely benefit from integrated medical care provided and coordinated in a primary health care setting. On the basis of the initial study results, these services were continued at a larger scale to further assess as well as mitigate health risks among this user population. Importantly, current doping legislation was demonstrated to be a major limitation to provision of adequate medical care for this user population, thus changes in legislation are crucial to avert this growing public health threat.
为改善外貌和提高运动成绩而非法使用合成代谢雄激素类固醇已成为一种全球范围内的物质使用障碍,尤其是在业余体育运动的男性中。使用合成代谢雄激素类固醇的人群的健康状况可能会受到损害,但针对这些使用者的医疗服务却很稀缺。因此,本项目的目的是开展一项质量保证研究,以评估在瑞士苏黎世的一家初级保健机构中,根据已发表的文献为合成代谢雄激素类固醇使用者提供当前最佳临床实践的可行性。
在苏黎世的阿鲁德成瘾医学中心设立了一个针对当前或过去使用合成代谢雄激素类固醇的初级医疗保健机构,为这一人群提供专门的医疗服务。评估这项质量保证研究可行性的报告和方法遵循试点研究的清单。本研究的主要可行性结果是对所接受服务的满意度(客户满意度得分)以及对服务的忠诚度(净推荐值)。这些客户指标已在医疗领域成功用于衡量患者体验,并推断未来的口碑宣传(即回访和推荐)。此外,目标是描述瑞士背景下的患者特征和物质使用行为。从2023年6月1日起患者可以在苏黎世获得这些服务。招募策略是在合成代谢雄激素类固醇使用者中进行口碑宣传以及关于该医疗服务的纸质广告(即传单)。资格标准基于关于反兴奋剂法律的法律限制和医学专业伦理原则。在初次就诊时,评估了重点患者病史,患者接受了体格检查、心理测量、仪器检查以及实验室检查。数据集使用描述性统计进行汇总。
总体而言,在2023年6月至12月期间共接待了34名符合条件的患者。在服务忠诚度(净推荐值:100;整数)以及患者对所接受服务的满意度(客户满意度得分:100%)方面取得了优异结果。患者通常是年轻的职业男性(平均年龄:38.5岁,标准差:8岁),教育程度超过义务教育水平。使用合成代谢雄激素类固醇的主要动机是出于审美目的。这些物质大多通过非医疗渠道获取。合成代谢雄激素类固醇的使用模式复杂,存在广泛的多药联用以及同时使用非法物质的情况。大多数患者出现了副作用,伴有多种身体和心理健康并发症。在体格检查以及实验室和仪器检查中发现了许多异常结果,尽管大多为轻度且短暂,但有些可能对健康结果有严重影响。
通过这项首次质量保证研究,我们证明在瑞士初级保健机构中,将当前最佳临床实践纳入为业余体育运动中使用合成代谢雄激素类固醇的使用者提供的服务似乎是可行的,且接受度很高。此外,这些患者可能会参与高风险行为,并且已证明共病医疗状况的患病率很高。使用合成代谢雄激素类固醇的使用者可能会从在初级卫生保健环境中提供和协调的综合医疗服务中受益。基于初步研究结果,这些服务在更大规模上继续开展,以进一步评估并减轻该用户群体中的健康风险。重要的是,当前的反兴奋剂立法被证明是为该用户群体提供充分医疗服务的主要限制因素,因此立法变革对于避免这种日益严重的公共卫生威胁至关重要。